The experimental study of the myocardium functional state under the influence of Diclocor in conditions of furazolidone-isadrine lesion

Authors

  • S. K. Shebeko National University of Pharmacy, Ukraine
  • O. S. Russkin National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/cphj.16.1379

Keywords:

myocardium, furazolidone-isadrine lesion, biochemical indicators, electrophysiological parameters, antialterative properties, drug Diclocor

Abstract

It has been presented the results of the studying on the influence of Diclocor on the functional state indicators of rat’s myocardium in conditions of furazolidone-isadrine lesion. After a medical application of Diclocor the normalization of both, general functional indicators − electrophysiological parameters of myocardium, and some blood biochemical indicators of experimental rats − the AST, LDH level, TBA-reactants, DC was observed. The obtained data testify about expressed anti-inflammatory action of the investigated medication in comparison with reference objects, which mechanism is caused by the membrane stabilizing and antioxidant types of activity as for the affected cardiomyocytes. Received results allow considering the perspectives of further experimental study of cytoprotective potential of original medication Diclocor on different models of inflammatory and dystrophic in condition of myocardium lesion.

References

Бобров В.О. Адаптаційні ішемічні та реперфузійні синдроми у хворих ішемічною хворобою серця: механізми, діагностика, обґрунтування терапії / В.О. Бобров, С.К. Кулішов. − Полтава: Дивосвіт, 2004. - 240 с.

Meek I.L., Picavet H.S., Vonkeman H.E. et al. Increased cardiovascular risk factors in different rheumatic diseases with the general population // Oxford (United Kingdom). — Р. Rheumatology. – 2012 – 52 (1). – Р. 210-216.

World Health Statistics 2012. − WHO, 2012. − 176 p. − http://www.who.int/healthinfo/ EN_WHS2012_Full.pdf.

T. Gusdinar, R. Herowati, R.E. Kartasasmita and I.K. Adnyana, Anti-inflammatory and Antioxidant Activity of Quercetin-3, 3’, 4’-Triacetate. Journal of Pharmacology and Toxicology.2011, 6: 182-18.

Експериментальне дослідження протизапальних властивостей препарату «Диклокор» / О.С. Попов, С.К. Шебеко, О.І. Шевченко, А.С. Шаламай // Клінічна фармація. – 2015. – Т. 19, № 4. – С. 35-39.

Zupanets I.A. The effect of the medication «Diclocor», containing diclofenac and quercetin, on clinico-biochemical parameters in rats with osteoarthritis / I.A. Zupanets, S.K. Shebeko, O.S. Popov // International Journal of Pharmacy and Pharmaceutical Sciences. – 2015. – Vol. 7 (9). – P. 101-104.

Diclocor is superior to diclofenac sodium and quercetin in normalizing biochemical parameters in rats with collagen-induced osteoarthritis / I.A. Zupanets, S.K. Shebeko, O.S. Popov, A.S. Shalamay // Inflammopharmacology. – 2016. – Р. 1-5. – DOI: 10.1007/s10787-015-0258-8.

Кардиоваскулярная патология при ревматоидном артрите. Монография/А.А. Дзизинский, Н.А.Храмцова//Иркутск: РИО ГИУВа – 2010. – 150 с.

Зайченко Г.В. НПВП: что нового в начале XXI века? // Медична газета «Здоров’я України». – Квітень 2014 р. – № 7 (332). – С. 30-31.

European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. − Strasbourg, 1986. − 52 p.

Доклинические исследования лекарственных средств: Методические рекомендации / Под ред. А.В. Стефанова. – К: Авиценна. – 2002. – 528 с.

Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. – 3-е изд. – М-ва: МедиаСфера. – 2006. – 312 с.

C. P. Chung, J. T. Giles, M. Petri et al., “Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: Comparison with control subjects from the multi-ethnic study of atherosclerosis,” Seminars in Arthritis and Rheumatism. 2012, vol. 41, no. 4, pp. 535–544.

Downloads

Published

2016-03-11

Issue

Vol. 20 No. 1 (2016)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2016 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).